Short Summary
Greenthread, LLC has filed a notice of appeal to the Federal Circuit challenging the PTAB’s finding that multiple claims of U.S. Patent 10,734,481 are obvious. The appeal focuses on alleged errors in claim construction, obviousness analysis, and consideration of secondary factors.
Detailed Summary
In a notice of appeal dated April 16, 2026, Greenthread, LLC contests the Patent Trial and Appeal Board’s final written decision that found claims 1‑9, 13, 15, 17, 20, 22‑27, 31‑32, and 34 of U.S. Patent 10,734,481 unpatentable as obvious under 35 U.S.C. § 103(a). The Patent Owner alleges the Board erred in its claim constructions, misinterpreted the prior art, failed to properly evaluate secondary considerations, and did not give adequate weight to the record evidence. The appeal has been filed with the United States Court of Appeals for the Federal Circuit, seeking reversal of the Board’s findings.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Monolithic Power Systems, Inc. vs Greenthread, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Cisco Systems, Inc.vsVideo Solutions Pte. Ltd.
Cisco Systems lost its IPR challenge against Video Solutions Pte. Ltd., with the PTAB rejecting claims of obviousness over Larson and Cai. The Board found that Petitioner failed to provide sufficient technical explanation for how a person skilled in the art would combine prior art references.
Cambridge Industries USA Inc. et al.vsApplied Optoelectronics, Inc.
Cambridge Industries has filed an IPR petition challenging all 17 claims of Applied Optoelectronics’ 10,313,024 optical‑module patent, asserting anticipation by two prior‑art references and urging the Board to institute review despite discretionary denial arguments.
Samsung Electronics Co., Ltd. et al.vsWilus Institute of Standards and Technology Inc.
Samsung has filed an IPR petition challenging U.S. Patent 11,159,210, asserting that all nine claims are obvious over the 802.11ax draft standard and two earlier patent publications. The petition relies on expert testimony and argues that the Board should not exercise discretionary denial.
AZURITY PHARMACEUTICALS, INC.vsHelsinn Healthcare S.A.
AZURITY PHARMACEUTICALS, INC. successfully secured institution of its IPR against Helsinn Healthcare S.A.'s patent (9186357) for anti-emetic agents. The Board found a reasonable likelihood that several claims would be unpatentable over prior art, specifically regarding the combination of triple-drug CINV treatment and superior NK antagonists.
Abbott Laboratories et al.vsMIRACOR MEDICAL SA
Abbott Laboratories has filed an IPR petition challenging Miracor Medical’s U.S. Patent 11,572,879 covering an implantable LVAD. The petition asserts that four prior‑art references render all asserted claims obvious under 35 U.S.C. §103. The case is currently pending before the PTAB.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.